Lupin launch a generic version of pain reliever for osteoarthritis in the US
Ibuprofen and Famotidine tablets (Duexise) had estimated annual sales of US $ 765 million in the US as if July 21
Ibuprofen and Famotidine tablets (Duexise) had estimated annual sales of US $ 765 million in the US as if July 21
The document is a global recommendation for circular packaging design. It will be updated and adapted to changes in the collection, sorting and recycling technology, as well as to future material development
The first lot of IPV will be supplied to the government this month as per the requirement of the Health Ministry
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
The hospital through its network performs more than 10,000 joint replacement surgeries annually
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
Subscribe To Our Newsletter & Stay Updated